The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy

SAT0492 Treatment Effects Measured by Dynamic Contrast Enhanced MRI and Ramris for Rheumatoid Arthritis

(2014) C. Beals et al.   ANNALS OF THE RHEUMATIC DISEASES

MRI comes of age in RA clinical trials

(2013) Charles Peterfy et al.   ANNALS OF THE RHEUMATIC DISEASES

Monitoring cartilage loss in the hands and wrists in rheumatoid arthritis with magnetic resonance imaging in a multi-center clinical trial: IMPRESS (NCT00425932)

(2013) Charles G Peterfy et al.   ARTHRITIS RESEARCH & THERAPY

The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound

(2012) Maxime Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial

(2012) Philip G Conaghan et al.   ANNALS OF THE RHEUMATIC DISEASES

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

(2012) Maxime Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

Brief Report: Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis

(2012) Maxime Samson et al.   ARTHRITIS AND RHEUMATISM

Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis

(2012) E. Choy   RHEUMATOLOGY

Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial

(2011) P. G. Conaghan et al.   ANNALS OF THE RHEUMATIC DISEASES

Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: A magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients

(2011) Mikkel Østergaard et al.   ARTHRITIS AND RHEUMATISM

Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints

(2011) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

Synovitis and Osteitis Are Very Frequent in Rheumatoid Arthritis Clinical Remission: Results from an MRI Study of 294 Patients in Clinical Remission or Low Disease Activity State

(2011) F. GANDJBAKHCH et al.   JOURNAL OF RHEUMATOLOGY

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu

(2010) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents

(2010) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

(2009) G. Jones et al.   ANNALS OF THE RHEUMATIC DISEASES

Reducing Invasiveness, Duration, and Cost of Magnetic Resonance Imaging in Rheumatoid Arthritis by Omitting Intravenous Contrast Injection -- Does It Change the Assessment of Inflammatory and Destructive Joint Changes by the OMERACT RAMRIS?

(2009) M. OSTERGAARD et al.   JOURNAL OF RHEUMATOLOGY

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

(2008) Stanley B. Cohen et al.   ARTHRITIS AND RHEUMATISM

Imaging in rheumatoid arthritis – status and recent advances for magnetic resonance imaging, ultrasonography, computed tomography and conventional radiography

(2008) Mikkel Østergaard et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET